A novel product for tendinopathy treatment
A novel product for tendinopathy treatment
批准号:
10306057
负责人:
David T Fung
金额:
$2.03万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-15 至 2022-05-31
关键词:
Adverse effectsAwardBioinformaticsBiological Response Modifier TherapyChronicDataDeteriorationDiseaseGoalsImpairmentPainParentsPathologyPerformanceResearch PersonnelSwellingTechnologyTendinopathyTendon structureTestingTherapeutic Effectcareer developmentcommercializationeffective therapynovelpain symptomresearch and developmenttendon rupturetraining opportunitytranscriptometranscriptome sequencingtranscriptomics
中文摘要
项目摘要
肌腱病是一种肌腱疾病,其特征是肌腱退化,经常导致肌腱断裂,
与疼痛、肿胀和表现受损有关。目前还没有治愈肌腱病。
因此,迫切需要有效的治疗肌腱病。家长奖的重点是
测试TenoGen,即将开发的产品,在减轻肌腱病方面发挥治疗作用
病理学和减轻肌腱病相关的疼痛和症状,而没有或只有最小的副作用。的
该补充项目的目的是为代表性不足的研究人员提供支持,
在母研究范围内为TenoGen的研发做出贡献。补充研究将侧重于
使用最先进的转录组RNA建立TenoGen治疗的转录组谱
测序(RNA-seq)和生物信息学技术。圆满完成拟议补编
该项目预计不仅将提供额外的数据,以加快研发和商业化的
TenoGen同时也为应聘者的职业发展提供了宝贵的支持和独特的机会。
1
英文摘要
Project Summary
Tendinopathy is a tendon disorder characterized by tendon deterioration that often leads to tendon rupture, and
is associated with pain, swelling and impaired performance. There is currently no cure for tendinopathy.
Therefore, there is an urgent need for effective treatments for tendinopathy. The parent award is focused on
testing the TenoGen, the product to be developed, exerts a therapeutic effect in mitigating tendinopathy
pathology and relieving tendinopathy-related pain and symptoms with no or minimal adverse effects. The
purpose of this supplement project is to provide support for an underrepresented researcher to participate and
contribute to the R&D of TenoGen within the scope of the parent study. The supplement study will focus on
establishing the transcriptome profile of TenoGen treatment using state-of-the-art transcriptomic RNA
sequencing (RNA-seq) and bioinformatics technologies. Successful completion of the proposed supplement
project is expected to not only provide additional data to accelerate for the R&D and commercialization of
TenoGen, but also provide valuable support and an unique opportunity for the candidate’s career development.
1
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
miRNA drug for tendinopathy
-
批准号:10709649
-
项目类别:
-
资助金额:$56.9万
-
财政年份:2022
-
负责人:David T Fung
-
依托单位:
miRNA drug for tendinopathy
-
批准号:10603377
-
项目类别:
-
资助金额:$73.74万
-
财政年份:2022
-
负责人:David T Fung
-
依托单位:
A novel product for tendinopathy treatment
-
批准号:10264118
-
项目类别:
-
资助金额:$83.16万
-
财政年份:2017
-
负责人:David T Fung
-
依托单位:
海外基金